

Epidemiology of Bronchiectasis

Anne E. O'Donnell MD May 17, 2018



GEORGETOWN UNIVERSITY

Disclosures

- Principal Investigator/Grant support for clinical trials
 - Insmed (inhaled liposomal amikacin)
 - Bayer (inhaled ciprofloxacin)
 - Aradigm (inhaled liposomal ciprofloxacin)
 - Parion (inhaled mucolytic for PCD)
- Foundation support for Bronchiectasis Registry
 - COPD Foundation
- Consultant
 - Novartis
 - Raptor/Horizon
 - Xellia
 - Bayer
 - Electromed
- NO FDA Approved therapies


Bronchiectasis "FAQ's"


- What is bronchiectasis?
- Why do I have it?
- Who else has it?
- Why is it increasing?
- Do I have COPD?
- What is the difference between bronchiectasis and NTM?

What is bronchiectasis?

- Abnormally dilated bronchi/bronchioles which leads to:
 - impairment of local host defenses
 - Chronic colonization with bacteria
 - Vicious cycle of airway inflammation and infection.
- Hence, an anatomic abnormality
- But, also a disease state
- We diagnose it with high resolution CT scan
- Symptoms
 - Chronic cough
 - Recurrent respiratory infections
- We are not including CF today......
 - Multiple etiologies

Normal Lung and Airways and the Lung of a Patient with Bronchiectasis







Bronchiectasis Alan F. Barker, M.D. N Engl J Med 2002; 346:1383-1393




Bronchiectasis






Courtesy of G. Huitt MD

A VICIOUS CYCLE OF INFECTION AND INFLAMMATION



Prevalence of Non-CF Bronchiectasis USA



Prevalence of NCFB Worldwide

Germany¹

- 2013: 0.07%
- Highest rate in men aged 75-84 years

United Kingdom²

- 2013: 0.56% in women, 0.49% in men
- Increased prevalence observed between 2004 and 2013

• Europe³

- Unknown prevalence
- Data gathering underway:
 EMBARC European
 Bronchiectasis Registry

• China4

- 2002-2004: 1.2% of individuals greater than 40 yrs
- More men than women
- "Not an orphan disease"

Republic of Korea⁵

 2008: 9.1% in a computed tomography screened "healthy" population




Why is the prevalence increasing?

- More patients actually have it
- Better diagnostic tools
 - CT chest
- More recognition by clinicians
- But there is often a delay in diagnosis
 - Cough is a non specific symptom
 - Antibiotics are an "easy" solution
 - Sputum cultures are not commonly done in primary care practices in US



Heterogeneous disease



- 1. Chalmers JD, et al. Am J Respir Crit Care Med. 2014;189:576-85.
- 2. Lonni S, et al. Ann Am Thorac Soc. 2015;12:1764-70



US NCFB Registry Data

TOTAL ENROLLEES N=2000	
Gender	79% female
Age, median	64 years
Race/ethnicity	89% non-Hispanic white 7% Black 4% Asian
Mean BMI	23.2 kg/m ²
Smoking	60% never 38% former 2% current
ENT co-morbidities	25%
Age at diagnosis, median	57 years






Why do I have bronchiectasis?

- No underlying disease
 - Idiopathic bronchiectasis
- "Post infectious"
- Immunologic deficiencies/abnormal "host"
- Rheumatologic abnormalities
- Congenital abnormalities
 - Alpha one anti-trypsin deficiency
 - Primary ciliary dyskinesia
 - Cystic fibrosis
- Aspiration



Focal vs Diffuse Bronchiectasis





Focal vs diffuse bronchietasis

Focal

- Anatomic abnormalities
 - Post infectious scarring
 - Airway obstruction
 - Tumor
 - Foreign body
- Aspiration
 - Neurologic disorders
 - Prior head and neck cancer

Diffuse

- Pulmonary only disease
 - Prior infection
 - Prior inhalation injury/aspiration
 - Asthma/COPD
- Sino-pulmonary disease
 - Congenital etiologies
 - Immunodeficiency
- Other systemic diseases
- Idiopathic




Evaluation for focal and diffuse bronchiectasis

- Overactive or underperforming immune system
 - Immunologic evaluation
 - IgG, IgA, IgA, Ig E
 - HIV testing
- Evaluation for other immunologic disorders
 - Allergic bronchopulmonary aspergillosis
 - Rheumatoid arthritis
 - Sjogren's syndrome
 - Inflammatory bowel disease
- Structural work up
 - Bronchoscopy
- Evaluation for reflux/aspiration

Evaluation of focal or diffuse bronchiectasis

- Does the patient need a genetic work up?
 - AAT deficiency
 - Evaluation for cystic fibrosis
 - Sweat test
 - Genetic evaluation
 - Co-morbidities
 - Specific microbiologic findings
 - Staphylococcus aureus
 - B. Cepacia
 - Evaluation for ciliary dysfunction
 - History
 - Neonatal respiratory distress
 - Ear and sinus problems
 - Infertility
 - Genetic testing

















Do I have COPD?

- COPD and bronchiectasis are not the same
- COPD
 - Smoker's disease
 - Occasionally COPD patients develop bronchiectasis
 - COPD patients with significant cough and sputum production should be evaluated for bronchiectasis
- Many bronchiectasis patients are misdiagnosed
 - COPD
 - Bronchitits
 - Asthma
 - pneumonia

Bronchiectasis and NTM

- Bronchiectasis is the anatomic abnormality
 - NTM is one type of infection that occurs in BE
 - Other bacteria may also be present
 - Pseudomonas/ other gram negatives and gram positives
 - Fibrocavitary vs nodular bronchiectasis
 - Fibrocavitary: NTM is a consequence of BE
 - Fibronodular: NTM may be the cause
 - Fibrocavitary: men and women
 - Fibronodular: female predominant

Fibronodular vs fibrocavitary





What makes me cough and produce sputum?

- Routine microbiology
 - Pseudomonas
 - Other gram negatives
 - Staphylococcus/streptococcus
 - nocardia
- Non tuberculous mycobacteria
- Fungi
- Country/region specific microbiology

Is there a blood test for my disease?

- Is there a test that can predict exacerbations?
 - No
- What about a test to assess bacterial load?
 - Not perfect
- A prognosticator biomarker?

EVIDENCE is lacking

What is my prognosis?

- Is my disease going to progress?
 - Perhaps
 - We have some predictors regarding outcomes
- How do I live better with my disease?
 - We will get to that
- Can I be cured of bronchiectasis?
 - Probably not, though surgery can be curative for some

What you need to ask your physician

- Confirm bronchiectasis
- Discuss an evaluation for causes
 - Treatable etiologies
 - Inherited diseases
- Confirm and monitor sputum cultures
 - Routine bacteria
 - NTM
- Targeted multimodality treatment
- New treatments/clinical trials

What I have learned from my patients

- Delay in diagnosis
- Lack of good explanations regarding the disease
 - Physicians need to do better
 - Team approach needed for the disease
- Psychosocial aspects of the disease
 - Cough/sputum
 - Fear of exacerbations/progression
- Burden of treatments

What I have learned from my patients



Bronchiectasis

- It is the underlying disease for many patients
- Worldwide incidence/prevalence increasing
- There are multiple causes
 - But we often don't identify a cause
 - "chicken and egg" question with NTM infection
- Evaluation should be tailored to the patient
- Microbiology results important

Resources

- NTM IR website
 - https://www.ntminfo.org
- Bronchiectasis tool box
 - http://bronchiectasis.com.au
- Bronchiectasis News Today
 - https://bronchiectasisnewstoday.com
- US Bronchiectasis Registry
 - https://www.copdfoundation.org/Research/Bronchiect asis-Research-Registry/Learn-More.aspx



COURSE CHAIR:

Anne E. O'Donnell, MD

MedStar Georgetown University Hospital Georgetown University Medical Center Washington, DC CO-COURSE CHAIR:

Timothy R. Aksamit, MDMayo Clinic
Rochester, MN

JULY 14, 2018
GEORGETOWN UNIVERSITY
WASHINGTON, DC







WWW.WORLDBRONCH.COM